Bruker Corp

BRKR remains in a Stage 2 advance with a bullish medium-term bias supported by higher highs and higher lows alongside rising moving averages, yet recent churning near multi-month resistance indicates a corrective consolidation; short-term timing is neutral as price pulls back into and holds above the 9 and 21 EMAs near the 50 DMA, so execution is best deferred until a pullback into the EMA envelope or defined support zones aligns for entry.

• ↑BSI bookings rose high single digits, led by biopharma demand
• ↑Introduced MyGenius Pro and expanded AI-driven metrology offerings
• ↓U.S. academic orders set to drop 20–25%, pressuring revenue